复发难治性DLBCL:客观缓解率26%

Blood

2017-08-03Article

13.164

影响因子

原标题:难治性弥漫性大B细胞淋巴瘤的预后:国际SCHOLAR-1研究结果

① 弥漫性大B细胞淋巴瘤(DLBCL),一线治疗的5年生存率为60-70%,约50%患者治疗后复发;② 难治性DLBCL的定义为,化疗过程中即一线化疗超过4个周期、后线治疗超过2个周期,最佳疗效为疾病进展或稳定,可自体干细胞移植后12个月内复发;③ SCHOLAR-1研究回顾性汇总分析2项III期临床研究和2项观察性队列研究,总计636例符合标准;④ 疗效从挽救性治疗开始计算,客观缓解率为26%,完全缓解率为7%,中位生存期为6.3个月,20%患者生存超过2年。

弥漫性大B细胞淋巴瘤(DLBCL) 化疗 耐药 侵袭性非霍奇金淋巴瘤

图片

Title:
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

DOI:
10.1182/blood-2017-03-769620

Abstract & Authors展开

Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. The international, multicohort retrospective non-Hodgkin lymphomaresearch (SCHOLAR-1) study retrospectively evaluated outcomes in patients with refractory DLBCL, which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed ≤12 months of autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence). Response rates and overall survival were estimated from the time that salvage therapy for refractory disease was initiated. Among 861 patients, 636 were included based on refractory inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis that characterizes response rates and survival for a population of patients with refractory DLBCL.

All Authors:
Michael Crump,Sattva S Neelapu,Umar Farooq,Eric Van Den Neste,John Kuruvilla,Jason Westin,Brian K Link,Annette Hay,James R Cerhan,Liting Zhu,Sami Boussetta,Lei Feng,Matthew J Maurer,Lynn Navale,Jeff Wiezorek,William Y Go,Christian Gisselbrecht

First Authors:
Michael Crump

Correspondence:
Christian Gisselbrecht

下载PDF原文

已完成

请稍等...

提示
提示